EP Patent

EP3644970A1 — New oral formulations of belinostat

Assigned to Acrotech Biopharma LLC · Expires 2020-05-06 · 6y expired

What this patent protects

The present invention relates to novel belinostat formulations suitable for oral administration, process for their preparation, pharmaceutical compositions comprising said formulations and their uses.

USPTO Abstract

The present invention relates to novel belinostat formulations suitable for oral administration, process for their preparation, pharmaceutical compositions comprising said formulations and their uses.

Drugs covered by this patent

Patent Metadata

Patent number
EP3644970A1
Jurisdiction
EP
Classification
—
Expires
2020-05-06
Drug substance claim
No
Drug product claim
No
Assignee
Acrotech Biopharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.